Holen Sie sich die Stockscreener-App
156.13
2.45%
-4.17
Handel nachbörslich:
156.73
0.60
+0.38%
Schlusskurs vom Vortag:
$160.30
Offen:
$160.54
24-Stunden-Volumen:
647.70K
Relative Volume:
0.71
Marktkapitalisierung:
$7.55B
Einnahmen:
$4.02B
Nettoeinkommen (Verlust:
$-142.16M
KGV:
-52.81
EPS:
-2.9563
Netto-Cashflow:
$518.49M
1W Leistung:
+2.59%
1M Leistung:
-7.91%
6M Leistung:
-12.61%
1J Leistung:
+14.37%
1-Tages-Spanne:
$155.50
$160.54
1-Wochen-Bereich:
$147.51
$163.42
52-Wochen-Spanne:
$132.58
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
156.74 | 7.72B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
448.27 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.86 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.15 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.72 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.09 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Are Wall Street Analysts Bullish on Charles River Laboratories Stock? - Yahoo Finance
Charles River Laboratories Inte (CRL) Stock Analysis: A 30% Upside Potential Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
Cell Banking Outsourcing Market: 16%+ CAGR (2026-2031), Expanding with Rising Demand for Biologics and Regenerative Medicine Services, Says Mordor Intelligence - GlobeNewswire Inc.
Is Charles River (CRL) Quietly Recasting Its Moat Around AI Pathology And Cell Therapy Services? - Yahoo Finance
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Should Higher Impairments and AI Investments Shape a New Capital Allocation Playbook for Charles River (CRL)? - simplywall.st
Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness - simplywall.st
Inspired Announces CFO Transition - The Manila Times
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MSN
The 5 Most Interesting Analyst Questions From Charles River Laboratories’s Q1 Earnings Call - Yahoo Finance
Charles River Laboratories Tops Q3 Estimates, Tightens Full-Year Outlook - MSN
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know - Yahoo Finance
Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform - simplywall.st
Charles River (CRL) reliance on international sales: What investors need to know - MSN
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Director Nancy Andrews gifts Charles River (CRL) shares to trust - Stock Titan
Charles River Laboratories stock (US1591881009): Q1 earnings beat with updated FY guidance - AD HOC NEWS
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - BioSpace
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River Laboratories stock (US1591881009): Shareholders approve 2026 incentive plan - AD HOC NEWS
Charles River Laboratories (CRL) Announces Approval of 2026 Long-Term Incentive Plan - GuruFocus
Director Steven Barg receives 1,438-share equity award at Charles River (NYSE: CRL) - Stock Titan
Charles River Labs (CRL) director receives 1,438-share equity award grant - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock grant - Stock Titan
Charles River Laboratories stock (US1591881009): Q1 earnings beat but FY2026 forecast cut - AD HOC NEWS
Number of shareholders of Charles River Laboratories International, Inc. – HAM:RV6 - TradingView
Charles River Laboratories International Inc (CRL) Stock Down 5. - GuruFocus
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down - MSN
Charles River Labs Shareholders Approve New Incentive Plan - TipRanks
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River (NYSE: CRL) investors approve 2026 incentive plan, pay and auditor - Stock Titan
Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors - marketscreener.com
Charles River (NYSE: CRL) director Abraham Ceesay receives 1,438-share stock grant - Stock Titan
Charles River Labs (NYSE: CRL) director Martin Mackay receives new stock grants - Stock Titan
Director at Charles River (NYSE: CRL) gets 1,438-share equity grant - Stock Titan
Charles River (NYSE: CRL) director receives stock grants instead of fees - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock award - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,973-share equity award - Stock Titan
Director Virginia M. Wilson (CRL) receives 1,438-share equity award at Charles River - Stock Titan
Director James Foster gets 1,860 Charles River (NYSE: CRL) shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Charles River (CRL) Enhances Digital Pathology Platform for Fast - GuruFocus
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow - 01net
Charles River (CRL) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Charles River expands AI-enabled digital pathology platform By Investing.com - Investing.com Canada
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):